share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

SEC announcement ·  Mar 22 17:48
Summary by Moomoo AI
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG, was involved in a transaction with the company's stock on March 20, 2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of the company's executives in its future.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more